We report a genome-wide association study of melanoma conducted by the GenoMEL consortium based on 317K tagging SNPs for 1,650 selected cases and 4,336 controls, with replication in an additional two cohorts (1,149 selected cases and 964 controls from GenoMEL, and a population-based case-control study in Leeds of 1,163 cases and 903 controls). The genome-wide screen identified five loci with genotyped or imputed SNPs reaching P o 5 Â 10 À7 . Three of these loci were replicated: 16q24 encompassing MC1R (combined P ¼ 2.54 Â 10 À27 for rs258322), 11q14-q21 encompassing TYR (P ¼ 2.41 Â 10 À14 for rs1393350) and 9p21 adjacent to MTAP and flanking CDKN2A (P ¼ 4.03 Â 10 À7 for rs7023329). MC1R and TYR are associated with pigmentation, freckling and cutaneous sun sensitivity, well-recognized melanoma risk factors. Common variants within the 9p21 locus have not previously been associated with melanoma. Despite wide variation in allele frequency, these genetic variants show notable homogeneity of effect across populations of European ancestry living at different latitudes and show independent association to disease risk.
doubling of risk. Variants of the MC1R (melanocortin-1 receptor) gene are associated with the combination of red hair, freckling and sun sensitivity, but MC1R may also have a nonpigmentation effect [7] [8] [9] [10] . A detailed genetic screen of pigmentation loci found that TYR (tyrosinase) gene variants and a haplotype spanning the ASIP (agouti signaling protein) locus were also associated with melanoma 11 . Increased intermittent exposure to UV radiation, rather than chronic exposure, is thought to be responsible for the continued increase in incidence in many populations 12 .
The most common high-penetrance melanoma susceptibility gene (CDKN2A) maps to 9p21 (ref. 13) . Germline CDKN2A mutations are carried by about 2% of all melanoma cases across populations 14 . The more cases of melanoma in a family, the more prevalent are CDKN2A germline mutations 15 , which seem to be associated with increased numbers of nevi in at least some families 16 .
This study was carried out by the GenoMEL Consortium (Supplementary Note), which focuses its efforts on studies of the genetic susceptibility to melanoma. The current genome-wide association study (GWAS) is based on population samples collected by GenoMEL participants to identify common genetic variants contributing to melanoma risk across populations of European ancestry living at different latitudes. In total, ten GenoMEL groups contributed 1,650 cases and 1,065 controls of European ancestry for this GWAS (Supplementary Table 1 ). Cases were selected in an effort to enrich for individuals that may have greater genetic predisposition to melanoma, through selection of cases with family history, multiple primaries or early onset of disease (see Online Methods). Genotyping results were also available from 1,824 French controls held by Centre National de Génotypage (CNG) and 1,447 UK controls from the 1958 Birth Cohort genotyped by the Wellcome Trust Case Control Consortium (WTCCC) 17 (Supplementary Fig. 1 ).
Following quality control and exclusion of persons of apparent non-European ancestry through principal components analysis (Supplementary Fig. 2 ), case-control analyses were conducted both (i) stratified (the primary analysis) and (ii) unstratified by geographical region (Fig. 1) . The unstratified analysis should provide greater power for associations common to multiple sample sets, whereas the stratified analysis protects against population stratification but is likely conservative in the absence of stratification. To confirm the effectiveness of our methods for dealing with stratification, we produced quantile-quantile plots (Supplementary Note). We selected regions with multiple SNPs (within 50 kb) that each had a Figure 2 Stratified CA trend tests. The Àlog 10 P values are from the CA trend test stratified (by geographical region) for genotyped and imputed SNPs in candidate regions for follow-up. Genotyped SNPs are shown in black and imputed SNPs in red; those SNPs that were followed up in the replication stage are indicated by a cross. The solid horizontal line indicates a P value of 10 À5 and the dashed line indicates a P value of 5 Â 10 À7 . The greyscale plots indicate extent of pairwise linkage disequilibrium (measured by r 2 ) between SNPs, estimated from our data using Haploview 23 . Imputed data were not used for this. The darkest shading (black) indicates r 2 Z 0.9, the next darkest 0.8 Z r 2 4 0.9, and so forth. The position of the SNPs relative to the graph is indicated by the lines between the two. rs1126809 is a functional SNP in TYR, so was genotyped in both replication sets. rs187142 was genotyped in the genome-wide data set and in the Leeds case-control samples but not genotyped in the GenoMEL replication set. rs10830253 is a replacement for rs1806319 and rs7188458 was genotyped in the genome-wide data set and in the GenoMEL replication set but was not genotyped in the Leeds case-control samples. Two other regions containing putative melanoma-susceptibility genes were examined. The chromosome 20 region contains ASIP, a pigmentation gene, identified by an analysis of pigmentation genes 11 which is in proximity to a region identified in a pooled genome-wide analysis 21 (none of these SNPs were on the genome-wide array); the chromosome 22 region was identified in an adjoining paper involving a GWAS of nevus count variation 22 . a Imputed SNPs.
L E T T E R S
P value o10 À5 from either the stratified or unstratified analysis and conducted imputation on these regions. We found five regions, on chromosomes 2, 5, 9, 11 and 16, in which at least one imputed or genotyped SNP achieved genome-wide significance (P o 5 Â 10 À7 , Table 1, Supplementary Table 2 and Fig. 2 ). The chromosome 2 region showed strong evidence of association in the unstratified analysis only and was not followed up as it contains the LCT (lactase) gene, whose SNPs are known to vary in frequency across Europe (Supplementary Table 2 ) 18 . To replicate the other loci harboring genome-wide significant SNPs, we analyzed an independent set of 1,149 cases and 964 controls from GenoMEL. As in the first cohort, cases were selected for enrichment of family history, multiple primaries or early onset of disease (see Online Methods and Supplementary Note). A further replication set comprised 1,163 cases and 903 controls from population-based studies from Leeds, UK. Samples were genotyped at the most significant SNPs from the GWAS, and also at any imputed SNPs that showed more significant association. If assays could not be produced or analyzed, alternative SNPs were genotyped.
Of the four regions that we attempted to replicate, only one (chromosome 5) showed no evidence of replication ( Table 1 and  Supplementary Table 3 ). The strongest association was with a region near the telomere of chromosome 16q: the three SNPs chosen for replication covered a 340-kb region with P values ranging between 7.99 Â 10 À11 and 7.54 Â 10 À17 in the GWAS sample and between 1.16 Â 10 À12 and 2.54 Â 10 À27 in the combined (genome-wide and replication phases) sample. This region includes several candidate genes, notably MC1R, CDK10 (involved in cell cycle regulation) and FANCA (which regulates genomic stability). A number of the 16q SNPs were reported earlier by Han et al. 19 , who in a GWAS examining hair color and skin pigmentation identified rs258322, which showed the strongest effect in both their and our study. Han et al. 19 showed that the rs258322 signal was explained by functional MC1R variants. In this study, stepwise regression analysis of 30 tag SNPs covering 1.4 Mb on 16q24 (Supplementary Table 4 ) showed evidence for association with three SNPs (rs258322, rs4785763, rs8059973); one of these (rs8059973) was not reported by the Han et al. study 19 and seems to have an association independent of the other two on melanoma risk. The magnitude of the association with rs258322 (per-allele odds ratio (OR) of 1.67, 95% confidence interval (CI) ¼ 1.52-1.83, Table 1 ) is notable, as it is comparable to that found by a recent meta-analysis of MC1R variants 9 , even though this SNP is distant from MC1R. The chromosome 11 region (overall strongest evidence for rs1393350, P ¼ 2.41 Â 10 À14 ) includes the TYR gene, which has previously been associated with melanoma 11 ; the coding variant (rs1126809) is included in the replication panel and shows a strong association in terms of OR for genotyped SNPs (OR ¼ 1.27, 95% CI ¼ 1.16-1.40, P ¼ 1.17 Â 10 À6 ; Table 1 and Supplementary Table 3) .
Stepwise regression analysis indicates that, after accounting for rs1393350, no other SNPs in the region were independently associated with melanoma (Online Methods and Supplementary Table 4) .
The third locus replicated is on 9p21, with the combined P value reaching 4.03 Â 10 À7 for rs7023329, which falls within the MTAP gene ( Table 1 and Supplementary Table 3) . Stepwise regression analysis of 11 tag SNPs covering a 2-Mb region on 9p21 showed evidence for the independent associations with one replicated SNP (rs7023329) plus another one, rs1011970, which is 246 kb centromeric and is within ANRIL, an antisense noncoding mRNA starting in the promoter of the p14ARF transcript of the CDKN2A gene and overlapping CDKN2B 20 (Supplementary Table 4 , Supplementary Fig. 3) . Notably, antisense transcripts in the MTAP region have been suggested for CDKN2A and CDKN2B 3 .
We also attempted to replicate findings from two other related genome-wide association studies 21, 22 . SNPs in these regions did not achieve the critical significance level for follow-up in our GWAS study, but the available evidence suggested these regions as strong candidates for containing melanoma susceptibility genes. A further pigmentation gene has been reported to be associated with melanoma (ASIP 11 ), adjacent to a reported melanoma locus recently identified by a pooling study 21 ; this chromosomal region is confirmed by the present data ( Table 1 and Supplementary Table 3) . In an accompanying article in this issue of the journal, Falchi et al. report a GWAS of nevus count variation based on volunteer twins from the UK, with replication in an Australian cohort 22 . Falchi et al. report two loci associated with nevus count and also show these are each associated with increased risk of melanoma. One of these loci overlaps with the chromosome 9 region identified here (Supplementary Note). The second nevus locus reported is on chromosome 22 and was also found to be associated with melanoma risk in our study ( Table 1 and Supplementary Table 3) .
Multiple logistic regression analysis of the three loci on chromosomes 9, 11 and 16 showed significant evidence for six SNPs being associated with melanoma risk (Supplementary Table 4) . No pairwise interactions between the most significant SNPs at the three loci were significant (all P 4 0. 19) , showing that the pattern of association with the three loci is consistent with a multiplicative model (Supplementary Table 4 ). Furthermore, examination of the associations by case phenotype category showed similar associations for family history, multiple primaries and early onset (Fig. 3) , although for some SNPs at the 9q21 and 16q24 loci the effect size was marginally weaker for earlyonset melanoma.
The strength of our study, which combines cases and controls from geographically distinct sites, lies in its ability to identify genetic variants that affect disease risk within diverse populations of European origin and to estimate the effects by population. Despite the variation in allele frequencies between groups (Supplementary Table 2 ) and the large differences in sun exposure between sites, the effect sizes for all three identified regions show marked homogeneity across the groups (Fig. 3) .
Given that the current study was well powered to detect variants with OR 4 1.5, it seems unlikely that there exist many additional common SNPs with a large effect on melanoma risk. Some of the genetic variants found to date to be associated with melanoma risk have also been found to be associated with pigmentation phenotypes [11] [12] [13] [14] [15] and nevus numbers 22 , but other variants may be involved. Further, Falchi et al. 22 found that adjustment of the SNP-melanoma association for nevus count reduced the strength of the SNP association with melanoma, suggesting that the SNP and nevus count are measuring in part the same disease-associated factor(s). Further studies are required to assess whether the loci characterized by the present study act mainly through melanoma-associated phenotypes and/or have independent associations with melanoma risk.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website. 
ONLINE METHODS
Study design. The study design is based on a GWAS of melanoma cases and controls, contributed by GenoMEL participating groups. Supplementary  Figure 1 contains an overview of the study. Groups were asked to identify, preferentially, melanoma cases either with a family history (but confirmed as not having a germline CDKN2A mutation), multiple primaries or onset before age 40 years. We argued that selecting for these criteria would 'enrich' for individuals with greater genetic predisposition and thereby increase power to identify genetic associations 24 . Family history was restricted to three cases for families from European populations and four cases for Australian participants to reduce the chance of including individuals with high-penetrance mutations. Controls were recruited by the same research groups from the same populations. Initially, the study design involved minimally 100 cases and 100 controls from each of the 10 centers, but this was expanded subsequently. Genotyping was conducted in two phases. The first phase involved genotyping through ServiceXS in Leiden, The Netherlands, using the Illumina HumanHap300 BeadChip version 2 duo array (with 317K tagging SNPs). Subsequent genotyping of cases was conducted at CNG in Paris using the Illumina Humancnv370k array. Control data were available from two further groups: French controls from CNG genotyped on the Illumina HumanHap300 BeadChip version 2 duo array and UK controls from the WTCCC (described in ref. 17 but based for this analysis on Illumina HumanHap300 BeadChip version 2 duo array genotyping).
We categorized the research groups by their geographical locations, but to enhance power we identified six geographical regions within which the data from individual groups were pooled. These geographical regions were Sweden (Lund and Stockholm), Australia (Brisbane, Sydney and Australian Melanoma Family Study (AMFS) sites), Italy (Genoa and Emilia-Romagna), UK/Leiden, France and Spain. Replication was carried out in a further independent set of enriched cases and controls supplemented by a population-based case-control study conducted in Leeds, UK ( Supplementary Fig. 1 ).
Sample sets. The cases and controls were selected from sets of samples accrued by the various contributing groups; these samples were recruited in different ways as described in the relevant publications. The contributing groups for the genome-wide genotyping were Barcelona 25 , Brisbane (cases 26 , controls 27 ), Emilia-Romagna 28 , Genoa 29 , Leiden, Leeds 16, 30 , Lund 31 , Paris 32 , Stockholm 33 and Sydney 34, 35 . The samples from Sydney included population-based earlyonset cases and matching controls from the Australian Melanoma Family Study 21 (AMFS, recruited in Sydney, Brisbane and Melbourne). Genotyping within the replication studies included samples from Poland 36 , Slovenia 37 and Tel Aviv. Ethical consent was obtained from all participants.
The Leeds-based case-control study recruited 1,274 population-based incident melanoma cases diagnosed between September 2000 and December 2006 from a geographically defined area of Yorkshire and the Northern region of the UK (63% response rate). Cases were identified by clinicians, pathology registers and via the Northern and Yorkshire Cancer Registry and Information Service to ensure overall ascertainment. For all but 18 months of the study period, recruitment was restricted to individuals with Breslow thickness of at least 0.75 mm. Some of these cases were genotyped genome-wide if they satisfied the criteria for case selection as described in Online Methods; the remainder (1,163 cases) were genotyped in the replication set.
Controls were ascertained by contacting general practitioners to identify eligible individuals. These controls were frequency-matched with cases for age and sex from general practitioners who had also had cases as part of their patient register. Overall there was a 55% response for controls (496 subjects); a subset of these controls was genotyped genome-wide and hence is excluded from the replication set. Controls were supplemented by a population-based group of 574 women who, following informed consent, agreed to participate in a study recording their history of sun exposure and sun bathing and for whom various measures of skin aging were recorded. DNA samples were also provided. A total of 903 controls was genotyped in the replication phase.
Sample handling and DNA preparation. Genome-wide genotyping for this study was conducted in Leiden by ServiceXS (SXS in Supplementary Table 1 ) and in Paris by Centre National de Génotypage (CNG in Supplementary  Table 1) (Supplementary Fig. 1) . Samples genotyped at ServiceXS were processed by the Department of Human and Clinical Genetics, Leiden University Medical Centre (LUMC). Sample lists were provided by the contributing GenoMEL centres and sample tubes and barcodes were returned to the centers from LUMC. Samples returned from the GenoMEL centers were then crosschecked against the manifest list. At the same time, phenotypic information was sent to the analysis center in Leeds. Processed samples were then checked for quality control by performing a single PCR test and examining DNA concentration and quantities; a round of sample replacement proceeded for samples that were considered to have failed quality control. A similar process applied to samples genotyped at CNG.
Quality control was performed for all samples before processing on the Illumina arrays. DNAs with a minimum concentration of 30 ng/ml (measured by NanoDrop(r) ND-1000) were subjected to a test PCR and checked on an agarose gel.
Replication genotyping was carried out using Taqman SNP genotyping assay (Applied Biosystems), with the exception of rs4911442, which was genotyped using the KASPar competitive allele-specific PCR system (KBiosciences) for the Leeds case-control study.
Quality control. Genotypes were called using the proprietary software supplied by Illumina (BeadStudio, version 3.2), with imported cluster centers based on HapMap samples (supplied by Illumina) and call threshold set at 0.15 as recommended by Illumina. Initially, no SNP was excluded from the analysis on the basis of quality control, but SNPs showing some evidence of association were screened intensively for signs of poor quality control. Some problems with poor chip quality were identified, and where possible samples with low (o97%) call rates were re-genotyped.
Sample exclusions. Samples were excluded for any of the following reasons: (i) call rate of less than 97% (of the total number of SNPs on the array); (ii) evidence of non-European origin from principal components analysis (PCA); (iii) sex as inferred from genotyping not matching reported sex; (iv) evidence of first-degree relationship or genetic identity with another sample. Sex was ascertained from genotype data by calculating the heterozygosity rate on the 9035 X-chromosome markers within Beadstudio; persons with 410% heterozygosity were classified as female, otherwise male. Relationship analysis was carried out in PLINK 38 using estimated identity-bydescent sharing.
SNP quality control. SNP quality control was assessed by considering a range of measures: (i) test of Hardy-Weinberg equilibrium for the different control groups; (ii) call rate; (iii) minor allele frequency (MAF); (iv) differences in MAF between genotyping centers; (v) test for homogeneity of ORs across regions; (vi) concordance of results with neighboring SNPs; (vii) where possible review of clusters from Bead Studio. Rather than using fixed thresholds, we considered these measures for all SNPs showing evidence of association at 10 À5 . We had no formal exclusion quality control criteria for SNPs; most SNPs either clearly failed quality control on multiple measures or raised no concern on any measure.
Principal components analysis and population stratification. To identify individuals of non-European ancestry, we thinned the SNPs to reduce linkage disequilibrium (LD) to a set of 67,315 SNPs such that no pair had r 2 4 0.2. The data were then combined with the HapMap data from 270 individuals of European, Asian and African origin. Before thinning, a quality control step was implemented; SNPs with call rate less than 97% were excluded as were SNPs with a Hardy-Weinberg P value o0.0001 in any case-by-genotyping-laboratory (SXS or CNG) or control-by-genotyping-laboratory analysis. PCA was applied to the remaining SNPs using EIGENSTRAT 39, 40 with the first two principal components (PCs) clearly separating the HapMap data into three distinct clusters according to ancestry. Most of our samples were clustered with the HapMap European samples ( Supplementary Fig. 2b) ; those that were not were excluded from subsequent analysis. The first two PCs captured 72% of the variation in the first 20 PCs (and 83% of the variation in the first 10 PCs).
The remaining European ancestry-only data were analyzed similarly by PCA implemented in EIGENSTRAT. After applying quality control, we thinned the SNPs such that pairwise r 2 never exceeded 0.5 (167,517 SNPs). Despite the fact that PCA makes no use of the geographical origin of the samples, plotting the first two PCs clearly grouped the samples by the center from which they were collected, with little overlap between centers ( Supplementary Fig. 2a ). The first PC corresponded roughly to latitude and the second PC to longitude as has been predicted elsewhere 18 . The third PC separated those groups from the NE or SW from those groups from the NW or SE (also predicted 18 ). This demonstrated that most of the individuals had ancestry reflective of the regions they had been collected from, although a few were clearly outliers from elsewhere in Europe.
For instance, although the majority of the Australian samples were clustered with the UK samples, several appeared to be more similar to the Italian samples, as did several of the French samples, suggesting that some had a southern European origin. Here the first three PCs capture 77% of the variation in the first 20 PCs (87% of the variation from the first 20 PCs is in the first 10). We were thus able to confirm that our groupings were roughly correct and we could account for stratification within Europe by adjusting for the first two or three PCs. Furthermore, by examining the loadings on the PCs, we could identify particular SNPs or regions with particularly strong loadings suggesting that these showed considerable variation across Europe. The regions with notably high loading were around LCT, OCA2 and HLA.
Association analysis. The primary analysis was a Cochran-Armitage (CA) trend test, stratified by region (see Study design, above). In addition, we carried out an unstratified CA trend test. Two further analyses were conducted to assist in interpretation of results: logistic regression analysis adjusted for region and the first three PCs (to adjust for any residual within-region population stratification) and a CA trend test stratified by study group defined by geographical center and genotyping laboratory. Equivalent 1-degree-offreedom stratified and unstratified trend tests were carried out for the X chromosome, in which males are treated as equivalent to homozygous females and a variance estimate that allows for the different variance of male and female contributions is used 41 .
Subgroup analyses of the different subtypes of case against all controls were also conducted for the most interesting SNPs.
Imputation. Imputation of ungenotyped SNPs was conducted using IMPUTE 42 , which predicts the genotypes of unobserved SNPs by means of a hidden Markov model using the genotype data at our observed markers and a set of known haplotypes (in this case the HapMap European samples). As the method is computationally intensive, we applied it only to those regions in which at least one SNP reached a P value of o10 À5 in either the CA trend test, the test stratified by group or the test stratified by region and further SNPs within 50 kb supported this result. We imputed 1 Mb on either side of any SNPs that reached the required P value as well as a 250-kb buffer on either side to avoid end effects. We assumed an effective population size of 11,400 and used a calling threshold of 0.9. We then applied both the CA trend test and a logistic regression adjusting for region.
Multiple regression analysis. Stepwise logistic regression was performed to identify those SNPs independently associated with melanoma within each of the validated regions (chromosomes 9, 11 and 16). We identified all SNPs that passed the quality control for imputation within the genome-wide analysis and that were within 1 Mb of the SNP giving the strongest evidence within each region. (The region covered on chromosome 16 is 1.4 Mb long because it is close to the telomere). Any SNP not associated with melanoma (P 4 0.01) was eliminated, and SNPs were thinned such that no pair had r 2 4 0.8. This left 50 SNPs from a total set of 480. The model assumed an additive effect on the logistic scale at the locus of interest, and analyses were adjusted for geographical region (as previously defined). Chromosomal regions were analyzed separately and in combination, and the analysis either included every individual or was restricted to individuals with complete genotyping at the markers being analyzed. At each step of the forward-selection procedure, the global significance of the model was evaluated, as was the significance of the new marker. The criteria for accepting a new marker were P o 0.001 for each marker included in the model from the likelihood ratio test and a decrement in the global P value of the model. Of the 5,456 individuals in the dataset, 4,959 (90.9%) had complete genotyping. The stepwise regression was conducted using Stata. Including individuals without complete data or considering regions separately made no qualitative difference to the results. Therefore, results are presented for analyses restricted to those with complete genotyping and a combined analysis of all three genetic regions.
Case category analysis. Cases were classified as having a family history if at least one first-degree relative had melanoma; individuals with multiple primary melanoma but no family history were classified in the 'multiple melanoma' category, and cases with onset before age 40 without either a family history or multiple primary melanoma were classified as 'early onset' (Supplementary Table 1) . Using these categories, we performed classical logistic regression adjusted for geographical region to estimate ORs for a given case category (for example, cases with family history versus controls) and to test for homogeneity of the SNP effect across regions using a likelihood ratio test. The homogeneity of ORs by case category was tested using trichotomous regression (for example, controls, cases with family history, cases without family history) and a likelihood-ratio test with 1 d.f. (that is, comparing a model where the ORs with and without family history are equal to a model where the two ORs are estimated).
Power to detect associations. We calculated the power to detect diseaseassociated regions in our initial genome-wide analysis at a P value of 5 Â 10 À7 and a sample size of 1,539 cases and 3,917 controls. We used effect sizes estimated in the replication stage in order to avoid bias, although this may be conservative since the cases from Leeds were population based and not selected as other case series. We assumed the marker being tested was in complete LD with the causative locus and that the baseline risk of disease was 0.05.
Our calculations show that we have 97% and 84% power to detect the most significant SNPs on chromosomes 16 and 11, respectively. However, we have very low power (B1%) to detect the region on chromosome 9. Although power is good (495%) to detect the previously identified region found on chromosome 20 (ref. 21) , the low frequency led to it not being tagged by our array. Considering the range of values we have the power to detect, we have at least 80% power to detect any SNP with an OR of 1.6 if MAF 4 0.05 (assuming sufficient coverage), an OR of 1.5 if MAF 4 0.08, an OR of 1.4 if MAF 4 0.12 or an OR of 1.3 if MAF 4 0.25. The lowest OR we have 80% to detect is 1.27 (when MAF ¼ 0.5). Thus, it is unlikely that we have missed any common variants with effect sizes 41.5 (unless coverage is poor in these areas). The study is not well powered to detect effects below 1.27, and thus there may well be other regions with SNPs of similar effect to those we found on chromosome 9 still to be discovered.
Replication analysis and Israeli samples. The genome-wide analysis involved European populations, and PCA was used to identify participants apparently not of European ancestry. Within the replication set, all samples were again derived from European populations with the exception of one population from Israel. Without genome-wide analyses to confirm comparability with the European genetic profile, we analyzed the replication data both with and without the Israeli samples. The analyses presented here include the Israeli samples but analyses excluding these samples are not qualitatively different from these.
